Poxel Initiates Pharmacokinetic (PK)/ Pharmacodynamic (PD) Study as part of the Phase 2a Clinical Program for PXL770, a Direct AMPK Activator for the Treatment of NASH Aug 5, 2019
Poxel Reports Financial Update for Cash and Revenue for the Second Quarter and the First Half 2019 and Provides Corporate Update Jul 15, 2019
Metavant and Poxel Announce Positive Topline Safety and PK/PD Results of Imeglimin in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3b/4 Jul 9, 2019
Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes Jun 25, 2019
Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society May 21, 2019
Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes Apr 9, 2019
Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH Apr 1, 2019
